Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab. A Randomized Phase II Trial.

Next Previous
Trial Profile

Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab. A Randomized Phase II Trial.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Catumaxomab (Primary)
  • Indications Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms IIPOP

    • Most Recent Events

    • 06 Jun 2017 Results assessing the potential survival benefit of an immediate postoperative intraperitoneal immunotherapy using catumaxomab in patients with gastric peritoneal carcinomatosis, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 10 Feb 2016 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
    • 05 Feb 2016 Planned primary completion date changed from 1 Nov 2014 to 1 Nov 2019, according to ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top